Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

Biotech Research Group, Seeking Alpha (5/23/16)
"Inovio Pharmaceuticals Inc., in collaboration with GeneOne Life Sciences, has found itself in an enviable position as the leader [in] developing a vaccine to combat the prolific Zika virus. . .the vaccine resulted in seroconversion, which is the development of detectable and specific antibodies in the blood and was apparent in all of the vaccinated primates. . .with Inovio reporting encouraging results in its early Zika study. . .the company is positioned at being first to market with a vaccine to treat Zika."

Charles Duncan
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company.
read more >
Jason McCarthy, Maxim Group (5/16/16)
"Inovio Pharmaceuticals Inc.'s Zika vaccine candidate generated robust anti-Zika immune responses in non-human primates. Human trials to follow. . .the vaccine induced seroconversion with the production of anti-Zika antibodies as well as anti-Zika T cells responses. This is positive as it suggests the immune system is being activated. . .Inovio continues to show a robust vaccine development platform that is both rapid and flexible that can play a vital role in the world of vaccines as these crisis (Ebola, MERS and now Zika) emerge as threats."

Ram Selvaraju, H.C. Wainwright & Co. (5/10/16)
"Inovio Pharmaceuticals Inc. announced its Q1/16 financial results. Total revenues were $8.1M, most of which were development payments from the DARPA Ebola grant. . .importantly, Inovio announced that it held meetings last month with both the FDA and the European Medicines Agency to discuss the Phase 2 results of VGX-3100 for the treatment of HPV-16/18 related high grade cervical dysplasia and the design of the pivotal Phase 3 trial for this candidate. . .the company is finalizing details for the trial and is on track to commence the Phase 3 study in 2016. We reiterate our Buy rating and $17 price target."

Charles Duncan, Piper Jaffray & Co. (5/9/16)
"Inovio Pharmaceuticals Inc. recently reported positive interim data from the Ebola Phase I study, triggering additional funding from the $45M DARPA grant, and its Zika vaccine is still guided to enter the clinic by YE16. In advance of increasingly visible clinical execution in both immunotherapy and infectious diseases, we reiterate our Overweight rating and $31 price target."

Jason McCarthy, Maxim Group (5/9/16)
"Inovio Pharmaceuticals Inc. continues to advance multiple programs forward and is heading towards a pivotal trial this year (VGX-3100). In our opinion, the data flow from multiple studies in 2016 should continue to provide incremental catalysts for investors."

Jason McCarthy, Maxim Group (5/2/16)
"Inovio Pharmaceuticals Inc. completed the previously announced acquisition of 'Needle-Free Injection Technology' from BioJect Medical Technologies. . .in addition, Inovio has been recently granted a $500K award to develop the non-invasive Needle-Free technology from the U.S. Army Small Business Innovation Research Program. . .the needle-free platform will continue to be developed and in the long-term could be a paradigm shifting technology in vaccine delivery for vaccinating large populations rapidly and more cost-effectively."

More Expert Comments

Experts Following This Company

Jim Birchenough – BMO Capital Markets
Yi Chen, Managing Director of Equity Research – Rodman & Renshaw
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Dorman Followwill, Partner and Director EIA – Frost & Sullivan Inc
Jason Kolbert, Senior Analyst – Maxim Group
Chen Lin What Is Chen Buying? What Is Chen Selling?
Jason McCarthy, Analyst – Maxim Group
Kevin McCarthy, Co-Managing Partner – Kayne Anderson MLP Investment Co.
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw
George Zavoico, Senior Equity Analyst – JonesTrading

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Inovio Pharmaceuticals Inc. Content